CS
LUMO

Credit Suisse’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Credit Suisse’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,681
Closed -$29K – 4265
2019
Q1 		$29K Buy
1,681
+225
+15% +$3.35K ﹤0.01% 3926
2018
Q4 		$20K Buy
+1,456
New +$25.6K ﹤0.01% 3834
2018
Q3 		– Sell
-1,319
Closed -$57K – 4040
2018
Q2 		$57K Sell
1,319
-1,037
-44% -$47.5K ﹤0.01% 3893
2018
Q1 		$153K Buy
2,356
+120
+5% +$8.5K ﹤0.01% 3745
2017
Q4 		$163K Sell
2,236
-3,756
-63% -$311K ﹤0.01% 3781
2017
Q3 		$548K Sell
5,992
-42
-0.7% -$3.22K ﹤0.01% 3485
2017
Q2 		$399K Buy
6,034
+3,049
+102% +$377K ﹤0.01% 3301
2017
Q1 		$648K Sell
2,985
-543
-15% -$77.6K ﹤0.01% 3127
2016
Q4 		$327K Buy
3,528
+671
+23% +$75.6K ﹤0.01% 3619
2016
Q3 		$386K Buy
2,857
+144
+5% +$14.3K ﹤0.01% 3549
2016
Q2 		$274K Sell
2,713
-1,935
-42% -$240K ﹤0.01% 3736
2016
Q1 		$761K Buy
4,648
+2,065
+80% +$419K ﹤0.01% 2933
2015
Q4 		$846K Buy
2,583
+116
+5% +$37.8K ﹤0.01% 2958
2015
Q3 		$796K Sell
2,467
-4,327
-64% -$1.9M ﹤0.01% 3027
2015
Q2 		$2.71M Buy
6,794
+2,865
+73% +$1.22M ﹤0.01% 2298
2015
Q1 		$1.94M Buy
3,929
+2,056
+110% +$797K ﹤0.01% 2419
2014
Q4 		$670K Buy
1,873
+96
+5% +$28.6K ﹤0.01% 3485
2014
Q3 		$342K Buy
1,777
+65
+4% +$14.3K ﹤0.01% 3865
2014
Q2 		$409K Sell
1,712
-7,306
-81% -$1.49M ﹤0.01% 3943
2014
Q1 		$2.3M Buy
9,018
+7,523
+503% +$2.3M ﹤0.01% 2402
2013
Q4 		$296K Sell
1,495
-604
-29% -$107K ﹤0.01% 4085
2013
Q3 		$354K Buy
2,099
+179
+9% +$28.8K ﹤0.01% 3696
2013
Q2 		$341K Buy
+1,920
New +$272K ﹤0.01% 3550

Other funds holding LUMO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Credit Suisse's LUMO Position: Q2 2019 in Review

Credit Suisse sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2019, closing a stake of 1,681 shares — an estimated $29K sold.

Credit Suisse first reported a position in LUMO in Q2 2013 and held it in 23 quarters. The position peaked at $2.71M in Q2 2015. 68 funds tracked by Wall St. Rank hold LUMO as of Q2 2019.

  • Credit Suisse reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Credit Suisse sold 1,681 Lumos Pharma, Inc. Common Stock shares in Q2 2019, an estimated $29K.
  • Credit Suisse first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 23 quarters.
  • Credit Suisse's Lumos Pharma, Inc. Common Stock position peaked at $2.71M in Q2 2015.
  • 68 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.